BioWorld

Oct. 12, 2009

Me-Too Drugs Not Dead Yet, but No Exceptions on Value

At last month's BioPharm America conference in San Francisco, biotech experts brushed aside the once-popular business model of using drug delivery or reformulation to provide incremental improvements to existing drugs. Read More

Money Raised Year to Date

When Biotechs Hit Hard Times, Leases Can Be the Last Straw

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Week in Washington

FDA Approvals in September

Phase I Clinical Trials Update: September 2009

Phase II Clinical Trials Update: September 2009

Pivotal/Phase III Clinical Trials Update: September 2009

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Non-U.S. Clinical Trials And Regulatory Actions: September 2009

FDA Submissions, Approvals And Other Actions: September 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for April 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

In the clinic for April 21, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...